Review explores potential of medicinal cannabis for sickle cell disease complications

The review compiles evidence that the endocannabinoid system is involved in pain modulation, inflammation, and vascular function, all of which are disrupted in sickle cell disease. Preliminary clinical trial results suggest potential benefits, though the evidence base remains limited.

Researchers conducted a comprehensive literature search of PubMed covering studies through 2024, focusing on the endocannabinoid system's role in various organ functions and its potential relevance to sickle cell disease complications.

Sickle cell disease causes severe chronic pain that often requires long-term opioid therapy, creating addiction risks and reduced quality of life. If cannabis-based treatments can reduce pain and opioid dependence in this population, it could significantly improve outcomes for the estimated 100,000 Americans with the disease.

Sickle cell disease disproportionately affects Black communities, who face additional barriers to both pain management and cannabis access. The intersection of racial health disparities, opioid crisis concerns, and evolving cannabis legislation makes this a particularly complex area of medicine.

This is a narrative review without systematic methodology. Clinical trial data in sickle cell disease specifically is extremely limited. The review is largely speculative, drawing on endocannabinoid system research in other conditions to make the case for SCD applications.